73 related articles for article (PubMed ID: 8898938)
1. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors.
Alvarez-Vallina L; Hawkins RE
Eur J Immunol; 1996 Oct; 26(10):2304-9. PubMed ID: 8898938
[TBL] [Abstract][Full Text] [Related]
2. Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein.
Gerstmayer B; Hoffmann M; Altenschmidt U; Wels W
Cancer Immunol Immunother; 1997; 45(3-4):156-8. PubMed ID: 9435862
[TBL] [Abstract][Full Text] [Related]
3. Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy.
Olguín-Contreras LF; Mendler AN; Popowicz G; Hu B; Noessner E
Front Immunol; 2021; 12():750478. PubMed ID: 34912334
[TBL] [Abstract][Full Text] [Related]
4. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement.
Chen L; Qian W; Pan F; Li D; Yu W; Tong L; Yang Y; Xu Q; Ding J; Dai R; Xian W; Zhu X; Ren P; Zhu H
Immunotherapy; 2024 Feb; 16(3):143-159. PubMed ID: 38126157
[TBL] [Abstract][Full Text] [Related]
5. Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation.
Emtage PC; Lo AS; Gomes EM; Liu DL; Gonzalo-Daganzo RM; Junghans RP
Clin Cancer Res; 2008 Dec; 14(24):8112-22. PubMed ID: 19088026
[TBL] [Abstract][Full Text] [Related]
6. Correction: Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with
Leland P; Kumar D; Nimmagadda S; Bauer SR; Puri RK; Joshi BH
J Transl Med; 2023 Sep; 21(1):636. PubMed ID: 37726828
[No Abstract] [Full Text] [Related]
7. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.
Finney HM; Lawson AD; Bebbington CR; Weir AN
J Immunol; 1998 Sep; 161(6):2791-7. PubMed ID: 9743337
[TBL] [Abstract][Full Text] [Related]
8. Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors.
Yuan G; Ye M; Zhang Y; Zeng X
Med Oncol; 2024 Apr; 41(5):126. PubMed ID: 38652178
[TBL] [Abstract][Full Text] [Related]
9. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
Goldenson BH; Hor P; Kaufman DS
Front Immunol; 2022; 13():841107. PubMed ID: 35185932
[TBL] [Abstract][Full Text] [Related]
10. Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors.
Muliaditan T; Halim L; Whilding LM; Draper B; Achkova DY; Kausar F; Glover M; Bechman N; Arulappu A; Sanchez J; Flaherty KR; Obajdin J; Grigoriadis K; Antoine P; Larcombe-Young D; Hull CM; Buus R; Gordon P; Grigoriadis A; Davies DM; Schurich A; Maher J
Cell Rep Med; 2021 Dec; 2(12):100457. PubMed ID: 35028604
[TBL] [Abstract][Full Text] [Related]
11. Unifying heterogeneous expression data to predict targets for CAR-T cell therapy.
Schreiner P; Velasquez MP; Gottschalk S; Zhang J; Fan Y
Oncoimmunology; 2021; 10(1):2000109. PubMed ID: 34858726
[TBL] [Abstract][Full Text] [Related]
12. Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors.
Abken H
Hum Gene Ther; 2021 Oct; 32(19-20):1011-1028. PubMed ID: 34405686
[TBL] [Abstract][Full Text] [Related]
13. Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.
Pinte L; Cunningham A; Trébéden-Negre H; Nikiforow S; Ritz J
Front Immunol; 2020; 11():608485. PubMed ID: 33658994
[TBL] [Abstract][Full Text] [Related]
14. A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells.
Bloemberg D; Nguyen T; MacLean S; Zafer A; Gadoury C; Gurnani K; Chattopadhyay A; Ash J; Lippens J; Harcus D; Pagé M; Fortin A; Pon RA; Gilbert R; Marcil A; Weeratna RD; McComb S
Mol Ther Methods Clin Dev; 2020 Mar; 16():238-254. PubMed ID: 32083149
[TBL] [Abstract][Full Text] [Related]
15. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.
Abbott RC; Cross RS; Jenkins MR
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947597
[TBL] [Abstract][Full Text] [Related]
16. CAR T Cells: A Snapshot on the Growing Options to Design a CAR.
Holzinger A; Abken H
Hemasphere; 2019 Feb; 3(1):e172. PubMed ID: 31723811
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression levels on tumor cells affect their immunosuppressive activity.
Zheng Y; Fang YC; Li J
Oncol Lett; 2019 Nov; 18(5):5399-5407. PubMed ID: 31612048
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
19. CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors.
Filley AC; Henriquez M; Dey M
Front Oncol; 2018; 8():453. PubMed ID: 30386740
[TBL] [Abstract][Full Text] [Related]
20. The expansion of targetable biomarkers for CAR T cell therapy.
Townsend MH; Shrestha G; Robison RA; O'Neill KL
J Exp Clin Cancer Res; 2018 Jul; 37(1):163. PubMed ID: 30031396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
